HIV modulates plasmacytoid dendritic cell (pDC) activation via Tolllike receptor 7, inducing type I IFN and inflammatory cytokines. Simultaneously, pDCs up-regulate the expression of indoleamine 2,3 dioxygenase (IDO), which is essential for the induction of regulatory T cells (Tregs), which function to down-modulate immune activation. Here we demonstrate the crucial importance of the noncanonical NF-κB pathway in the establishment of this immunoregulatory phenotype in pDCs. In response to HIV, the noncanonical NF-κB pathway directly induces IDO and involves the recruitment of TNF receptorassociated factor-3 to the Toll-like receptor/MyD88 complex, NF-κB-inducing kinase-dependent IκB kinase-α activation, and p52/RelB nuclear translocation. We also show that pDC-induced Tregs can inhibit conventional DC (cDC) maturation partially through cytotoxic T-lymphocyte antigen (CTLA)-4 engagement. Furthermore, CTLA-4 induces IDO in cDCs in a NF-κB-inducing kinase-dependent way. These CTLA-4-conditioned cDCs can in turn induce Treg differentiation in an IDO-dependent manner. Thus, the noncanonical NF-κB pathway is integral in controlling immunoregulatory phenotypes of both pDCs and cDCs.
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T he mechanisms of generation and the role of CD4
+ regulatory T cells (Tregs) in HIV remain under investigation, but may be key to understanding and controlling the damaging immune activation observed in chronic infection (1) . Treg frequency has been shown to inversely correlate with immune activation (2, 3) . Furthermore, deregulation of Treg function and Treg/Th17 cell ratios may impair beneficial mucosal Th17 responses during chronic infection (4) . These data suggest that Tregs can play an important role in HIV infection by modulating immune activation during acute and chronic infection. The precise mechanisms of Treg generation in HIV infection are still largely unknown, however. In this context, plasmacytoid dendritic cells (pDCs), the major type I IFN producers on viral infection, seem to play an important role in Treg generation. pDCs can promote the differentiation of Tregs through several mechanisms, including the expression of inducible T-cell costimulatory ligand or the tryptophanmetabolizing enzyme indoleamine 2,3 dioxygenase (IDO) (5) (6) (7) (8) .
We recently demonstrated that HIV-1-activated pDCs induce Treg differentiation from naïve CD4 + T cells through a CD4-, endocytosis-and Toll-like receptor (TLR)-7-dependent pathway (7) . Importantly, using the competitive inhibitor 1-methyl-tryptophan and siRNA knockdown, we determined that expression of the enzyme IDO by pDC is absolutely required for Treg generation.
An immunomodulatory role for IDO and Tregs has been suggested in animal models of simian immunodeficiency virus infection (9, 10) , where nonpathogenic infection was correlated with IDO expression in blood and lymphoid tissue. Taken together, these data implicate the IDO pathway as a critical element in the induction of Tregs in HIV infection and the control of associated deleterious inflammatory consequences. Thus, elucidating the molecular mechanisms of IDO induction and its consequences on the differentiation of Tregs in the setting of HIV infection is important.
Results
Induction of IDO in pDC Is Independent of the Canonical NF-κB Pathway. IDO induction on HIV stimulation in pDCs is dependent on the TLR-7-MyD88 pathway, as demonstrated previously by an siRNA knockdown of TLR-7 and MyD88 (7) . These experiments were performed with HIV laboratory strains, however. We stimulated primary pDCs with several primary HIV isolates, all of which induced IDO in the pDCs (Fig. 1A) , confirming the physiological relevance of this pathway. To identify the signaling pathways that induce IDO in pDCs, we focused on the activation of TLR by HIV. pDCs express both TLR-7 and TLR-9, but only TLR-7 is triggered by HIV (11) . One consequence of TLR-7 triggering is recruitment of the MyD88/IRAK4/TNF receptor-associated factor (TRAF)-6 complex, which in turn leads to activation of the IκB kinase (IKK)-α/IKK-β/IKK-γ (NEMO) complex for activation of the canonical NF-κB pathway through ubiquitylation of IκBs and translocation of p50/ RelA into the nucleus (12) . In cooperation with the MAP kinase pathway and AP-1 translocation, the NEMO complex coordinates the transcription of inflammatory cytokines, such as TNF-α, and through recruitment of interferon regulatory factor 7 induces type I IFN transcription in a TRAF3-dependent manner (12) (13) (14) .
In human pDCs, blockade of type I IFN did not reduce HIVinduced IDO expression, indicating that it is not required for IDO regulation (Fig. 1B) (15) . We then examined the roles of other downstream TLR pathways in IDO induction. To determine whether the canonical NF-κB pathway is required for IDO induction, we made use of a NEMO-binding domain inhibitory peptide (NBD) to inhibit the interaction of NEMO with IKK-β (16) . Activation of the GEN pDC line through TLR-7 (with its agonist resiquimod/R848) induced activation of the canonical NF-κB pathway, measured by p50 nuclear translocation (Fig. 1C) . Preincubation with the NBD peptide (WT) inhibited p50 translocation compared with the control peptide (mutant), and also inhibited TNF-α production ( Fig. 1 C and D) . However, NBD peptide blockade did not inhibit IDO induction (Fig. 1E) , indicating that the canonical NF-κB pathway is not involved in IDO transcription.
Noncanonical NF-κB Pathway Is Required for TLR-Induced IDO Expression. Recently, the noncanonical NF-κB pathway was implicated in CD40 and glucocorticoid-induced TNF receptor ligand-induced IDO expression in conventional dendritic cells (cDCs) and pDCs, respectively (17, 18) . Activation of some cell surface receptors, including TNF family members and various TLRs (17, 19, 20) , has been linked to the activation of an alternative NF-κB pathway in addition to the canonical NF-κB pathway. The noncanonical NF-κB pathway involves activation of NF-κB-inducing kinase (NIK) and phosphorylation of IKK-α dimers, leading to phosphorylation of p100, cleavage pf p100 into p52, and translocation of p52/RelB complexes to the nucleus (19, 21) . Indeed, HIV activation in primary pDCs and TLR-7 engagement induced cleavage of p100 into p52 ( Fig. 2A ). Constitutive activation of and cleavage of p100 was observed in some instances, and HIV stimulation induced further activation (Fig. 2B ). On average, HIV stimulation induced up-regulation of p52 by 3.33 ± 0.94-fold (P = 0.0257, Student t test; n = 5). The synthetic TLR-7 agonist R848 also induced p100 processing into p52 (Fig. 2C) , as well as translocation of p52 to the nucleus, in GEN pDCs ( Fig. 2D) , indicating that the noncanonical NF-κB pathway is generally activated on TLR-7 triggering in pDCs. Elevation of p100 protein levels upon activation by R848 suggests coupled cotranslational processing of p100, as described previously (22) .
Importantly, siRNA knockdown of NIK and IKK-α ( Fig. S1 ), two crucial components for activating the noncanonical pathway, inhibited expression of IDO (Fig. 2E) . Thus, in five experiments, NIK knockdown induced a 3.0 ± 1.4-fold inhibition of IDO expression (P < 0.05, Student t test). Activation of the noncanonical NF-κB pathway and processing of p100 are independent of IKK-β and NEMO, but strictly dependent on IKK-α (23), explaining why blockade of NEMO did not affect IDO expression. On the other hand, IKK-α is not strictly required for activation of the canonical NF-κB pathway (24) . Knockdown of TLR-7, TLR-9, MyD88, and NIK all inhibited IDO expression by TLR-7 and TLR-9 agonists (Fig. 2E ). In five independent experiments, knockdown of TLR-7 induced 60% ± 16% less IDO expression (P < 0.05, Student t test). Low levels of IFN-γ did not induce IDO expression under these conditions, as reported previously (25) . These data indicate that TLR-7-mediated activation of the noncanonical NF-κB pathway is important for IDO expression in human pDCs.
Activation of NIK Correlates with TRAF3 Recruitment to the TLRMyD88 Complex. The upstream mechanisms by which the noncanonical pathway is activated remain to be fully characterized (19) . NIK is crucial for the phosphorylation of IKK-α and the formation of a ternary complex with IKK-α and p100. In B cells, NIK expression is normally maintained at low levels through sequestration by TRAF3 and constitutive ubiquitylation by cellular inhibitor of apoptosis (cIAP). On ligation of B-cell activating factor receptor by B-cell activating factor, TRAF3 is recruited to the receptor and ubiquitylated, releasing NIK, which can then associate with IKK-α and p100. Given that endosomal TLR-7 triggering in pDCs is linked to recruitment of TRAF3 for interferon regulatory factor 7 phosphorylation (14) and possibly MAPK activation (26), we hypothesized that TRAF3 recruitment might free NIK for activation of the noncanonical NF-κB pathway. Triggering of TLR-7 on pDCs induced early phosphorylation of p100 (Fig. 3A) ; the average up-regulation at 30 min was 1.9 ± 0.3 fold (P = 0.045; n = 3). Immunoprecipitation of MyD88 showed an association with TRAF3 on TLR triggering (Fig. 3B) . Furthermore, TRAF3 dissociated from NIK, as demonstrated by coimmunoprecipitation of NIK and TRAF3 (fold reduction of TRAF3-NIK association, 1.56 ± 0.23, P = 0.027, n = 3) (Fig. 3B) . At the same time, immunoprecipitation of NIK and IKK-α demonstrated that NIK associates with IKK-α on TLR triggering (Fig. 3 B and C) (fold NIK binding to IKK-α at 30 min vs. time 0, 2.35 ± 0.79; P = 0.0054; n = 4). These data show that TRAF3 is recruited to the TLR/MyD88 complex, inducing dissociation of NIK from TRAF3 and association of NIK with IKK-α for p100 phosphorylation.
Noncanonical NF-κB Binding Sites Directly Bind RelB and Drive IDO Expression. The IDO promoter contains three partial p52/RelB binding sites (AGGAGACACA, GGGAGACAGA, and AGGA-GAAAGA), the consensus noncanonical binding sequence being PuGGAGAPyTTPu (27) around position −2000 (28) . To determine whether these binding sites are sufficient to interact with p52/RelB and induce gene transcription on TLR triggering, we transfected pDCs with plasmids containing repeats of one IDO promoter sequence (AGGAGAAAGA), the consensus noncanonical NF-κB binding sequence (GGGAGATTTG), or the canonical NF-κB binding site (GGGGACTTTCC) (27) ahead of the firefly luciferase gene. R848 triggering induced luciferase expression by 4 h, driven by the canonical NF-κB promoter, the full noncanonical promoter, and, importantly, the IDO promoter (Fig. 4) . CpG also induced IDO promoter-driven luciferase activity, albeit with slower kinetics (Fig.  4A) . NIK knockdown by siRNA abolished expression of luciferase driven by the IDO or the noncanonical promoter sequences, but not of luciferase driven by the canonical NF-κB binding site (Fig. 4B) , controlling for the specificity of the noncanonical-driven luciferase induction. This finding suggests that TLR-7 and TLR-9 triggering induces NIK activation and p52/RelB binding to the upstream IDO promoter sequences for gene expression.
To demonstrate direct binding of p52/RelB to the IDO promoter, we performed ChIP analysis by RelB pull-down. RelB immunoprecipitation showed binding to two of three noncanonical binding sequences in the IDO promoter (GGGAGACAGA and AGGAGAAAGAT, the two proximal sequences) (Fig. 5) . Again, NIK knockdown abrogated binding of RelB to the promoter sequences, indicating that NIK activation is required for RelB translocation and binding to the IDO promoter sequences. Taken together, these data demonstrate that TLR-7 triggering is linked to Fig. 1. HIV induces IDO in pDCs. (A) Primary pDCs were incubated for 24 h with an HIV laboratory strain (SF162) or infectious molecular clones (JR-CSF, CH058, CH077, or CH106). Expression of IDO and actin were monitored by RT-PCR, and normalized IDO expression was quantified by densitometry. One representative experiment of three is displayed. (B) Primary pDCs were preincubated with blocking monoclonal antibodies for IFN-α, IFN-β, and IFN-α/β-R2 (α−IFN) or isotype controls (IgG) for 1 h, followed by the addition of HIV MN (300 ng/mL p24 Eq ) for 18 h. RNA was extracted, and IDO or β-actin levels were measured by RT-PCR. Normalized IDO expression in three experiments was quantified, and is represented as mean ± SD. (C) NBD inhibits p50 translocation induced by TLR-7. GEN pDCs were preincubated with NBD [either WT or mutant (MT)] for 1 h, after which R848 was added for 30 min and nuclear translocation of p50 was measured. Pooled data from three experiments are shown (*P < 0.05, Student t test). (D) GEN pDCs were preincubated with NBD (50 μM) for 1 h, followed by the addition of R848. TNF-α was measured after an 18-h incubation by cytokine bead array (BD Biosciences). Results are shown as mean ± SD of an experiment conducted in triplicate (*P < 0.05, Student t test). Data in C and D are representative of at least three experiments. (E) Expression of IDO in GEN pDCs was measured by RT-PCR after incubation with the NBD peptide and stimulation by R848. Normalized IDO expression in three experiments was quantified and is represented as mean ± SD.
noncanonical NF-κB activation, leading to binding of p52/RelB to the IDO promoter and IDO transcription. 
cells (inducible Tregs) that can inhibit autologous naïve CD4
+ T-cell proliferation and the maturation of and inflammatory cytokine secretion by cDCs (7). Knockdown of IDO abrogates the differentiation of these Tregs. We investigated the mechanisms by which Tregs suppress cDC phenotype and function. pDC-induced Foxp3 + Tregs express cytotoxic T-lymphocyte antigen (CTLA)-4 ( Fig. S2) , and CTLA-4 was found to be partially implicated in their inhibition of cDC activation. Whereas the Tregs containing the CD25 + fraction (7) of pDC-activated CD4 + T cells blocked TNF-α secretion by LPS-stimulated cDCs, CTLA-4-blocking antibodies partially restored TNF-α secretion (Fig. S3) .
Furthermore, the Treg-containing CD25 + fraction of pDC-activated CD4 + T cells induced IDO in monocyte-derived dendritic cells (moDCs) (Fig. 6A) . As described previously, CTLA-4-Ig induced IDO expression in cDCs (29) (30) (31) (Fig. 6B) , supporting a direct role of CTLA-4 on Tregs in this effect. Furthermore, NIK knockdown in cDCs abrogated the induction of IDO induced by CTLA-4-Ig (Fig.  6B) . Thus, these data confirm the involvement of the noncanonical NF-κB pathway in IDO up-regulation by CTLA-4 in cDCs. CTLA-4-Ig-treated cDCs were functionally impaired, displaying impaired inflammatory cytokine secretion (Fig. S4) . Moreover, when cocultured with naïve CD4 + T cells, they induced the differentiation of CD25 + T cells capable of inhibiting the proliferation of autologous naïve CD4
+ T cells in a secondary suppressor assay ( Fig. 6C and Fig  S5) . CTLA-4-Ig synergized with LPS to facilitate DC-mediated Treg induction (Fig. 6C) . Addition of the IDO inhibitor 1-methyl tryptophan blocked the generation of Tregs by CTLA-4-Ig-treated cDCs, demonstrating that Treg generation is IDO-dependent (Fig.  6C) , as described previously (32) . Thus, CTLA-4-Ig-treated DCs Previous studies have demonstrated synergy between CTLA-4-Ig and CD40 triggering for IDO expression (31) in cDCs, and these interactions are known to act through noncanonical NF-κB signaling to modulate IDO transcription (17) . A crucial role for the noncanonical pathway in IDO induction also has been uncovered on GITR triggering in pDCs, together with type I IFN (18) . Our observation that CTLA-Ig can induce IDO in human cDCs adds to the described cell-extrinsic role of CTLA-4, mediating CD80 and CD86 depletion on the surface of antigen-presenting cells through transcell endocytosis (33) .
The precise mechanisms linking TLR activation to noncanonical NF-κB activation are unclear (26) . Our data indicate that TRAF3 is recruited to the MyD88 complex upon TLR engagement, which releases NIK from TRAF3-mediated destabilization. Indeed, TRAF3 is known to regulate the turnover of NIK, through interaction with TRAF2/cIAP and K48-linked ubiquitylation of NIK. Recruitment of TRAF3 to TLR-4 leads to TRAF3 K-48 and/or K63 ubiquitylation for MAPK or type I IFN signaling, respectively (34) , which may allow the release of NIK from TRAF3/TRAF2/cIAP-mediated ubiquitylation and its accumulation for auto-activation and triggering of the noncanonical NF-κB pathway. TRAF3 is essential for type I IFN signaling (19) , and its recruitment to MyD88 in the endosomes on TLR-7 triggering (13, 35) may allow the release of NIK and result in stabilization. Although the noncanonical pathway is typically a slow process, possibly owing to the kinetics of NIK synthesis and stabilization, cotranslational processing of p100, or compartmentalization of TLR signaling for IFN-α induction, rapid activation of the noncanonical NF-κB pathway also has been observed in pDCs activated through GITR (18) or on LPS stimulation of monocytic cells (20) , and may comprise early initiation followed by an amplification phase. Early activation may result from constitutive noncanonical NF-κB activation, which is further enhanced on receptor triggering (Fig. 1) . Basal RelB expression may finally determine the strength and kinetics of noncanonical NF-κB signaling (36) . The results from the present study, although obtained mostly with the human GEN pDC line, also likely apply to primary pDCs, given that GEN cells share many of the functional attributes of primary pDCs, including TLR-induced IDO expression (37, 38) . Recent studies in primary mouse pDCs also support the idea that IDO expression is controlled by the noncanonical NF-κB pathway upon triggering by TNF family receptors or TGF-β (37, 38) .
The transcriptional control of IDO is complex and contextdependent. Although type I and type II IFNs alone can induce IDO in many cell types through STAT1, they are not necessarily strictly required for IDO expression in some instances, such as after systemic injection of TLR-9 agonists (39). In our studies and those of others (15), type I IFNs are not required for IDO induction in human pDCs. IDO can be induced independent of STAT1 and IFN regulatory factor 1 by inflammatory cytokines (e.g., TNF-α, IL-6) that activate p38 MAPK and NF-κB pathways (40, 41) , by prostaglandin E2 acting through prostaglandin receptor EP2 (42) or by TGF-β (37, 38) , underscoring the complexity of signaling required for IDO induction in different cell types and physiological situations. So-called "reverse signaling" through cell surface receptors [e.g., GITR (28) ] activates the noncanonical NF-κB pathway, which in synergy with IFN-α induces IDO in murine pDCs, presumably through STAT1 phosphorylation (18) . In human pDC, it appears that PI3K-p38 MAPK mediated phosphorylation of STAT1 can occur independently of type I interferons after TLR stimulation (43, 44) . Therefore, based on our data and others' (15) we speculate that direct TLR activation of STAT1 may bypass the requirement for IFN signaling, and p52/ RelB may act in synergy with or facilitate STAT1 binding to IFNstimulated response element or IFN-γ-activated sequence elements for IDO induction (Fig. S6) . Other pattern-recognition receptors, such as Dectin-1, can activate the noncanonical NF-κB pathway; however, RelB activation is concomitantly antagonized by Dectin-1-induced Raf-1 activation to induce Th1-and Th17-polarizing cytokines (45) , reflecting an integrated regulation of the pathway with differential impacts on T-cell differentiation. Overall, our results point to a central role of noncanonical NF-κB signaling in the establishment of tolerance through the control of IDO expression and Treg generation by pDCs and cDCs during HIV infection. Type I IFN secreted by pDCs on HIV infection may amplify induction of IDO in an autocrine/paracrine fashion through either STAT1 signaling or the noncanonical NF-κB pathway (46) , further expanding the spectrum of IDO-expressing cells and strengthening IDO associated immune modulation. These results provide molecular targets to modulate immune activation in HIV and other pathologies involving pDC activation (47) . Chronic activation of TLR by HIV or bacterial products in pDCs and cDCs, accompanied by chronic type I IFN and inflammatory cytokine secretion, likely participates in disease progression. Manipulation of Treg expansion in HIV infection through the noncanonical pathway regulation of IDO in pDCs and cDCs may limit the damaging Tcell overactivation that characterizes progressive disease.
Materials and Methods
Primary pDCs were stimulated for 24 h by 30 ng/mL of p24 equivalent HIV laboratory strains (SF162) or infectious molecular clones (JR-CSF, CH058, CH077, and CH106), obtained through the Center for HIV-AIDS Immunology. pDCs and the GEN line were stimulated by 2 μg/mL of CpG oligonucleotide (GGGGACGACGTCGTGGGGGGG; Integrated DNA Technologies) or 0.5-1 μM resiquimod (R848; 3M). Detailed information is provided in SI Materials and Methods.
